Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603469 | 0.92 | DDR2 (0.52) | CACNA1BCACNA1HPOLBMEN1GAA | |
| SCHEMBL15575223 | 0.88 | POLB (0.51) | CACNA1BCACNA1HPOLBMEN1GAA | |
| SCHEMBL15574695 | 0.88 | POLB (0.49) | CACNA1BPOLBMEN1GAAKMT2A | |
| SCHEMBL16990693 | 0.86 | HDAC1 (0.55) | POLBMEN1GAAKMT2ADDR2 | |
| SCHEMBL16990667 | 0.86 | DDR2 (0.62) | CACNA1BDDR2 | |
| SCHEMBL16990690 | 0.84 | DDR2 (0.61) | DDR2 | |
| SCHEMBL16990628 | 0.83 | DDR2 (0.59) | CACNA1BDDR2 | |
| SCHEMBL16990624 | 0.82 | DDR2 (0.67) | DDR2 | |
| SCHEMBL16990651 | 0.82 | DDR2 (0.63) | DDR2 | |
| SCHEMBL15573192 | 0.80 | DDR2 (0.54) | POLBMEN1GAAKMT2ADDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | CACNA1B 3266/4885CACNA1H 4015/4885POLB 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.